Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Key Inclusion Criteria:
1. Healthy males or females as determined by assessments at the Screening Visit.
For Parts A, B, C, and E:
a. Participants must be at least 18 years of age and no more than 55 years of age at the Screening
2. For Part D:
a .Participants must be at least 60 years of age and no more than 80 years of age at the Screening
Key Exclusion Criteria:
1. Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
2. History of seizure disorder, any other condition that increases the risk of seizure
3. Has a clinically significant sleep disorder, including insomnia or sleep apnea.
Primary outcome measure(s)
Part A: Incidence and severity of Treatment-Emergent Adverse Events of oral single ascending doses of ORX142 in healthy adult subjects — From enrollment to the Follow-Up Visit 13 days post-discharge Safety and Tolerability as assessed by AEs and SAEs
Part B: Incidence and severity of Treatment-Emergent Adverse Events of oral single ascending doses of ORX142 in the fasted and fed states — From enrollment to the Follow-Up Visit 13 days post-discharge Safety and Tolerability as assessed by AEs and SAEs
Part C: Incidence and severity of Treatment-Emergent Adverse Events of oral multiple ascending doses of ORX142 in healthy adult subjects — From enrollment to the Follow-Up Visit 13 days post-discharge Safety and Tolerability as assessed by AEs and SAEs
Part D: Incidence and severity of Treatment-Emergent Adverse Events of oral single oral doses of ORX142 in healthy older adult subjects — From enrollment to the Follow-Up Visit 13 days post-discharge Safety and Tolerability as assessed by AEs and SAEs
Part E: Incidence and severity of Treatment-Emergent Adverse Events of oral of single oral doses of ORX142 in acutely sleep-deprived healthy adult subjects — From enrollment to the Follow-Up Visit 13 days post-discharge Safety and Tolerability as assessed by AEs and SAEs
Trial sites (3)
Facility
City
Region
Status
Site #1
Lincoln
Nebraska
Recruiting
Site #2
Eatontown
New Jersey
Recruiting
Site #3
New York
New York
Recruiting
More Centessa Pharmaceuticals (UK) Limited trials in the USA
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.